<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">

  <title><![CDATA[Category: News | Bioops]]></title>
  <link href="http://bioops.info/category/news/atom.xml" rel="self"/>
  <link href="http://bioops.info/"/>
  <updated>2016-06-28T17:00:47+00:00</updated>
  <id>http://bioops.info/</id>
  <author>
    <name><![CDATA[Bioops]]></name>
    
  </author>
  <generator uri="http://octopress.org/">Octopress</generator>

  
  <entry>
    <title type="html"><![CDATA[CFDA Approved BGI's Next Generation Sequencing Diagnostic Products]]></title>
    <link href="http://bioops.info/2014/07/cfda-approved-bgis-next-generation-sequencing-diagnostic-products/"/>
    <updated>2014-07-04T14:32:11+00:00</updated>
    <id>http://bioops.info/2014/07/cfda-approved-bgis-next-generation-sequencing-diagnostic-products</id>
    <content type="html"><![CDATA[<p>只收集一些相关资料，不评论。
<a href="http://www.sda.gov.cn/WS01/CL0051/102239.html">http://www.sda.gov.cn/WS01/CL0051/102239.html</a>
2014年6月30日，国家食品药品监督管理总局经审查，批准了BGISEQ-1000基因测序仪、BGISEQ-100基因测序仪和胎儿染色体非整倍体（T21、T18、T13）检测试剂盒（联合探针锚定连接测序法）、胎儿染色体非整倍体（T21、T18、T13）检测试剂盒（半导体测序法）医疗器械注册。这是国家食品药品监督管理总局首次批准注册的第二代基因测序诊断产品。</p>

<p>该批产品可通过对孕周12周以上的高危孕妇外周血血浆中的游离基因片段进行基因测序，对胎儿染色体非整倍体疾病21-三体综合征、18-三体综合征和13-三体综合征进行无创产前检查和辅助诊断。</p>

<p><a href="http://www.knowgene.com/question/677">http://www.knowgene.com/question/677</a>
BGISEQ-1000基因测序仪基于Complete Genomics平台，配套的试剂盒为胎儿染色体非整倍体（T21、T18、T13）检测试剂盒（联合探针锚定连接测序法）。CG平台的特点是通量高，但周期较长，因此BGISEQ-1000应该主要会应用于全国范围内的样品，集中测序分析；</p>

<p>BGISEQ-100基因测序仪基于Ion Torrent平台，配套的试剂盒为胎儿染色体非整倍体（T21、T18、T13）检测试剂盒（半导体测序法）。Ion Torrent平台的特点是测序周期短，可灵活部署，BGISEQ-100有很大可能会被部署到有一定业务量的大中型医院，就地采样、测序、分析并出具报告.</p>

]]></content>
  </entry>
  
  <entry>
    <title type="html"><![CDATA[NGS Startups]]></title>
    <link href="http://bioops.info/2013/03/ngs-startups/"/>
    <updated>2013-03-26T00:00:00+00:00</updated>
    <id>http://bioops.info/2013/03/ngs-startups</id>
    <content type="html"><![CDATA[<p><h1><a href="https://www.23andme.com/" target="_blank">23andme</a></h1>
<h3><a href="http://en.wikipedia.org/wiki/23andMe" target="_blank">Wiki</a>:</h3>
23andMe is a privately held personal genomics and biotechnology company based in Mountain View, California that provides rapid genetic testing. The company is named for the 23 pairs of chromosomes in a normal human cell. Their personal genome test kit was named &#8220;Invention of the Year&#8221; by <em>Time</em> magazine in 2008.
<h3><a href="https://www.23andme.com/about/jobs/" target="_blank">Jobs</a>:</h3>
<strong>Engineering:</strong>
HPC Systems Administrator<br />
Senior Software Engineer<br />
Software Engineer<br />
Storage Systems Architect/Engineer
<strong>Science:</strong>
Backend Software Engineer<br />
Health Content Scientist<br />
Research Assistant<br />
Scientist<br />
Statistical Geneticist<br />
Statistical Geneticist focusing on Parkinson&#8217;s Disease<br />
Survey Methodologist<br />
User Interface Designer
<h1><a href="http://www.binatechnologies.com/" target="_blank">Bina</a></h1>
<h3><a href="http://www.binatechnologies.com/company" target="_blank">About</a>:</h3>
Bina is the big data science platform accelerating personalized medicine for researchers and clinicians requiring fast, accurate and scalable genomic analysis. The word &#8220;Bina&#8221; means &#8220;knowledge&#8221; or &#8220;insight&#8221;, translated from both Persian and Hebrew. We use cutting-edge big data technologies to dramatically reduce the amount of time and money required to process raw genetic data in order to generate insights for personalized medicine. Bina was started by a team of Stanford and Berkeley researchers and entrepreneurs, with the vision that whole genome sequencing (WGS) is just the beginning of a brighter future. Bina is accelerating personalized medicine, one genome at a time.
<h3><a href="http://www.binatechnologies.com/company/joinus" target="_blank">Jobs:</a></h3>
Big Data Software Architect<br />
Senior Software Engineer<br />
Senior Computational Biologist<br />
Senior Data Scientist<br />
Senior Applications Support Scientist<br />
Senior Bioinformatics Scientist</p>

<p><a href="http://techcrunch.com/2013/03/25/with-6-5m-in-tow-bina-technologies-wants-to-bring-big-data-insight-to-genomic-sequencing/" target="_blank">TechCrunch: With $6.25M In Tow, Bina Technologies Wants To Bring Big Data Insight To Genomic Sequencing</a></p>

<p><strong><em>(to be continued)</em></strong></p>
]]></content>
  </entry>
  
  <entry>
    <title type="html"><![CDATA[Sequencing Cost (2013 Feb)]]></title>
    <link href="http://bioops.info/2013/02/sequencing-cost/"/>
    <updated>2013-02-20T00:00:00+00:00</updated>
    <id>http://bioops.info/2013/02/sequencing-cost</id>
    <content type="html"><![CDATA[<p><div><section>
<h2><a href="http://www.nature.com/news/gene-sequencing-leaves-the-laboratory-1.12454" target="_blank">Reasonably priced genomes</a></h2>
<section></section><section>Although no reports of big innovations in DNA sequencing are expected at a major conference this week, the current cost and capabilities of the technology now make medical applications worthwhile.</section>
<table>
<thead>
<tr>
<th scope="col">Name</th>
<th scope="col">Machine cost</th>
<th scope="col">Read length (bases)</th>
<th scope="col">Cost per megabase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Illumina MiSeq</td>
<td>US$125,000</td>
<td>500</td>
<td>14–70 cents</td>
</tr>
<tr>
<td>Illumina HiSeq</td>
<td>US$690,000</td>
<td>300</td>
<td>4–5 cents</td>
</tr>
<tr>
<td>PacBio RS</td>
<td>US$695,000</td>
<td>4,575</td>
<td>$2–17</td>
</tr>
<tr>
<td>Ion Torrent PGM</td>
<td>US$49,000</td>
<td>400</td>
<td>60 cents–$5</td>
</tr>
<tr>
<td>Ion Torrent Proton</td>
<td>US$224,000</td>
<td>200</td>
<td>1–9 cents</td>
</tr>
</tbody>
</table>
Source: The companies; Travis Glenn</section></div></p>

<p>
<div></div></p>
]]></content>
  </entry>
  
  <entry>
    <title type="html"><![CDATA[Nature: 染色体镶嵌性、年龄和癌症之间的关系]]></title>
    <link href="http://bioops.info/2012/05/relationship-of-clonal-mosaicism-aging-cancer/"/>
    <updated>2012-05-08T00:00:00+00:00</updated>
    <id>http://bioops.info/2012/05/relationship-of-clonal-mosaicism-aging-cancer</id>
    <content type="html"><![CDATA[<p>5月6日的Nature同时发布了两篇研究方向非常相似的论文，揭示了染色体镶嵌性会随着年龄的增长而增加，并与癌症发生有一定关联。</p>

<p><a href="http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.2270.html" target="_blank">一篇</a>由<a href="http://www.cancer.gov/" target="_blank">National Cancer Institute (NCI)</a>的<a href="http://dceg.cancer.gov/about/staff-bios/chanock-stephen" target="_blank">Stephen Chanock</a>领导完成。将 31,717个癌症患者和26,136健康人血液或口腔拭子的SNP芯片数据分析比较。健康人中染色体复制异常的比率随着年龄而增长，50岁以下0.23%，到了70多岁就飙到了1.91%。平均下来，癌症患者中染色体复制异常的比率比健康者高一些（0.97% VS 0.74%）。有些白血病患者被诊断出来前一年的血液样本中的染色体复制异常也比健康人普遍。</p>

<p>从<a href="http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.2271.html" target="_blank">另一篇</a>来自<a href="https://www.genevastudy.org/" target="_blank">Gene Environment Association Studies Consortium (GENEVA)</a>。他们分析了超5万人血液样本的SNP芯片数据，发现50岁以下人的基因组样本中，复制异常低于0.5%，而在50岁之后的人中迅速增长至2–3%。有很多复制异常都在以前发现的和血液癌症有关的位点上。虽然这些有“污点记录”的位点只占所发现的异常位点的3%，统计学分析表明，有复制异常的人得血液癌症的概率是正常人的十倍。</p>

<p>笔记：上面涉及到一些概率，我没仔细看文章，可能理解有错。人体细胞复制不可靠。年老的人更容易得癌症。50岁是个坎儿。生孩子要趁早。</p>
]]></content>
  </entry>
  
  <entry>
    <title type="html"><![CDATA[上了火的RNA-seq]]></title>
    <link href="http://bioops.info/2012/04/rna-studies-under-fire/"/>
    <updated>2012-04-25T00:00:00+00:00</updated>
    <id>http://bioops.info/2012/04/rna-studies-under-fire</id>
    <content type="html"><![CDATA[<p>Nature News今天的一篇<a href="http://www.nature.com/news/rna-studies-under-fire-1.10502" target="_blank">评论</a>，说是现在越来越多人使用高通量的RNA数据，但忽略了统计分析的严密性和重要性，而得到了一些值得怀疑的结论。</p>

<p>举了两个例子。</p>

<p>第一个，2010年，Harvard的<a href="http://www.hms.harvard.edu/dms/neuroscience/fac/dulac.php">Catherine Dulac</a>和<a href="http://www.neuro.utah.edu/people/faculty/gregg.html">Christopher Gregg</a>在Science上发了一篇<a href="http://www.sciencemag.org/content/329/5992/643.long" target="_blank">文章</a>，号称1300多个小鼠的基因都属于烙印基因（<a href="http://en.wikipedia.org/wiki/Genomic_imprinting" target="_blank">imprinted gene</a>：两个等位基因，一个表达一个沉默）。但是Standford的Tomas Babak用同样的数据得到了不同的结果，并于2012年3月将其<a href="http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1002600" target="_blank">分析结果</a>发表在PLoS  Genetics上。Babak认为原文章所用的统计方法会有很高的假阳性。</p>

<p>另一个例子就是前段时间引起巨大争议的关于RNA编辑广泛存在的那篇<a href="http://www.sciencemag.org/content/333/6038/53" target="_blank">文章</a>。后来又有多篇评论发表在Science上，强烈置疑该文章分析方法的可靠性。</p>

<p>造成这种争议的原因是什么呢？</p>

<p>一是RNA-Seq还没有像DNA测序一样建立起一个标准化的、错误偏差少的分析方法。</p>

<p>二是这些文章一般号称在生物学上某一点上取得了突破，所以一般是搞生物的来审核，缺少搞数学和统计的人把关。</p>

<p>个人觉得：很少有懂统计的人把生物理解的很清楚，更少有搞生物的把统计学好的，现在生物大数据时代，都需要补补课了。这两篇文章因为是有了“突破性的发现”，所以很多双眼睛在盯着，引起了怀疑。至于其他灌水文章，也不知道能有多少篇把统计方法用对的。这算是方法论的问题，只要提出来了，多探索一般能有个定论。更可怕的是搞科研的为了发文章，不惜更改数据或忽略负面数据，前几天不是有人<a href="http://online.wsj.com/article/SB10001424052970204571404577257513760102538.html" target="_blank">抱怨</a>癌症治疗的研究大部分都是在骗人么？！</p>

<p>希望以后有所改观，至少做到自重吧。</p>
]]></content>
  </entry>
  
</feed>
